Minocycline as an adjunctive therapy in patients with bipolar mania
- Conditions
- Health Condition 1: G- Mental Health
- Registration Number
- CTRI/2021/12/038752
- Lead Sponsor
- Central Institute of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion criteria for group 1 (Minocycline) and Group 2 (Placebo)
1. Male inpatients satisfying the ICD 10-DCR[1993] criteria of Bipolar affective disorder, current episode mania with YMRS score of >20.
2.Age group of 18-50 years.
3.Drug naive or drug free patients for minimum 2 weeks for mood stabilisers/antipsychotics and 4 weeks for depot antipsychotics.
4.Those who give informed consent for participating in the study.
Exclusion criteria for group 1 (Minocycline) and Group 2 (Placebo)
1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
2.Significant current/ past medical or neurological illness including severe hepatic disease and history of severe head injury .
3.Known hypersensitivity to Tab. Minocycline or any of its components.
4.Patients who had received ECT in last 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of Tab. Minocycline (200mg/day) as an adjunctive therapy assessed by YMRS BPRS and CGI scores in patients with bipolar mania.Timepoint: Baseline, 2 weeks and 6 weeks
- Secondary Outcome Measures
Name Time Method Change in the levels of IL-1β-converting enzyme, iNOS,and Bcl-2 in patients receiving adjunctive Tab. Minocycline (200 mg/day).Timepoint: Baseline, 2 weeks and 6 weeks